Fibritor
Generic: Pemafibrate
Daily Dose:
Duration:
Alternatives (2)Cheaper & Alternative Brands (0.1 mg)
Same active generic (Pemafibrate), same form (Tablet), exact same strength (0.1 mg)
Clinical Prescribing Information
Medical monograph and safety information for healthcare professionals & patients.Indications & Clinical Uses
Fibritor tablet is indicated as adjunctive therapy to diet to reduce TG in patients with dyslipidemia, including familial hyperlipidemia.
Dosage & Administration
Adult dose
: The usual adult dosage is 0.1 mg of pemafibrate orally administered twice daily. The dose may be individualized according to the patient’s age and symtoms. Pemafibrate can be taken with or without food.
Use in children
: The safety of Pemafibrate in children has not been established.
Renal impairment
: Pemafibrate should be used with caution in patients with renal impairment defined as estimated glomerular filtration rate (eGFR) less than 30 mg/min/1.73 m2. A lower starting dose or prolong dosing intervals should be considered. The maximum dose is 0.2 mg daily.
Hepatic impairment
: Pemafibrate should be used with caution in patients with severe hepatic disorder.
Contraindications
Pemafibrate is contraindicated in-
patients with known hypersensitivity to Pemafibrate or to any of the excipients.
patients with severe hepatic disorder, Child-Pugh grade B or C cirrhosis, or biliary obstruction
patients with cholelithiasis
pregnant or possibly pregnant women
patients receiving concomitant
cyclosporine or rifampicin
Side Effects & Adverse Reactions
Gastro-intestinal disorder (e.g. nausea, diarrhoea, abdominal pain), jaundice, skin rashes, gallstones, myotoxicity.
Warnings & Precautions
An increased risk of rhabdomyolysis has been reported with other fibrates when co-administered with an HMG-CoA reductase inhibitor (statin), especially in case of pre-existing muscular disease. Fibritor should be used with caution in patients receiving statins. Muscle toxicity should be suspected in patients presenting diffuse myalgia, myositis, muscle cramps and weakness and/or marked increase in (CK>5 times the upper limit of normal range). In such cases, treatment with Fibritor should be stopped. Fibritor should be used with caution in patients with hepatic disorder or those with history of hepatic disorder. Abnormal liver function tests may occur. The plasma concentration of Fibritor may increase in patients with hepatic disorder (Child-Pugh grade A cirrhosis, etc). Liver function should be monitored periodically during treatment. Since cholelithiasis has been reported, Fibritor should be used with caution in patients with a history of cholelithiasis. Since increase in LDL-cholesterol levels may occur, LDL-cholesterol levels should be monitored periodically during treatment.
Pharmacology & Mechanism of Action
Hypertriglyceridemia along with reduced HDL-C are risk factors of Atherosclerotic Cardiovascular Disease (ASCVD). Factors such as sedentary lifestyle, lipid-rich diet etc. makes it more difficult to control high triglyceride (TG).
Fibrates are considered as the preferred treatment for reducing TG. They act primarily by binding to and activating peroxisome proliferator activated receptor alpha (PPARα), a nuclear receptor. But conventional fibrates have low selectivity and potency for binding to PPARα. As a result, sometimes they fail to achieve desired TG level and often associated with various side effects.
Pemafibrate, a new selective PPARα modulator, is strongly effective in treating hypertriglyceridemia and low HDL-C levels. Its unique Y-shaped structure allows it to bind tightly to the PPARα receptor.
Pemafibrate structure contains benzoxazole and phenoxyalkyl side-chains along with common fibric acid group, which ensures-
High selectivity for PPARα
Strong interaction with the receptor
Maximum activation of the receptor
Thus, Pemafibrate shows over 2,500-fold greater potency for PPARα compared to conventional fibrates and provides better therapeutic outcome.